JHU TRAC: Training and Supporting the Next Generation of TB Researchers

JHU TRAC：培训和支持下一代结核病研究人员

• 批准号: 10431020
• 负责人: Richard E. Chaisson
• 金额: $ 99.66万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-16 至 2027-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10431020
• 关键词: Address; Animal Model; Area; Baltimore; Basic Science; Bioinformatics; Biological Assay; Biometry; Biostatistics Core; Cessation of life; Clinical; Clinical Pharmacology; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Communities; Computer Models; Cost Effectiveness Analysis; Country; Data; Development; Diagnosis; Diagnostic; Discipline; Disease; Economic Models; Education and Outreach; Effectiveness; Engineering; Ensure; Epidemic; Epidemiology; Funding; Generations; Goals; Government; HIV; Health; Health Services Accessibility; Image; Immunology; In Vitro; Interdisciplinary Study; Intervention; Knowledge; Laboratories; Mentors; Microbiology; Mission; Modeling; Mycobacterium tuberculosis; Output; Participant; Pathogenesis; Pharmaceutical Preparations; Pharmacology; Pharmacology Study; Policies; Population Dynamics; Prevention; Productivity; Protocols documentation; Public Health Nursing; Research; Research Personnel; Role; Sampling; Scientist; Services; Site; Specific qualifier value; Strategic Planning; Sum; Talents; Training; Training Programs; Training Support; Translational Research; Tuberculosis; Underrepresented Populations; United States National Institutes of Health; Universities; World Health Organization; animal imaging; base; biosafety level 3 facility; career; clinical research site; design; diagnostic tool; drug development; efficacy validation; epidemiological model; evidence base; experience; global health; imaging facilities; improved; innovation; interdisciplinary collaboration; large datasets; mathematical model; medical schools; meetings; member; microbial; multidisciplinary; next generation; novel; novel diagnostics; pandemic disease; pharmacokinetics and pharmacodynamics; pharmacometrics; pre-clinical; public health intervention; radiotracer; recruit; research study; symposium; synergism; tool; training opportunity; translational model; tuberculosis treatment

ABSTRACT — JHU TRAC OVERALL Tuberculosis (TB) remains a major global health problem, and advances in the basic and clinical sciences are urgently needed to make progress towards the World Health Organization’s End TB Strategy goal of reducing TB deaths by 95% and new cases by 90% between 2015 and 2035. The Johns Hopkins University (JHU) Center for Tuberculosis Research (CTR) has been a global leader in TB pathogenesis, translational models, diagnostics, drug development, pharmacology, public health interventions, and epidemiological and economic modeling for more than two decades. Research emanating from the CTR and JHU has transformed the treatment of TB infection and disease, elucidated interactions between TB and HIV drugs, validated the efficacy and effectiveness of new diagnostic tools, and contributed to the development of evidence-based policies for global TB control, based on the epidemiology and population dynamics of TB. However, to make further progress in efforts to achieve the END TB goals, additional innovative, cross-disciplinary and impactful research is critical and a new generation of TB scientists must be recruited and trained, particularly among groups nationally underrepresented in health-related research (UHRR). We have assembled a multidisciplinary team of researchers from multiple departments spanning four JHU schools (Medicine, Public Health, Nursing and Engineering), with complementary expertise in microbial pathogenesis, immunology, animal models, imaging, clinical trials, diagnostics, epidemiology, pharmacology and pharmacometrics, computational modeling, and biostatistics, in order to provide added value to the TB research enterprise at JHU optimize training opportunities for junior investigators and support for new, interdisciplinary collaborations, with the goal of addressing key knowledge gaps in TB research. The JHU TRAC team comprises 58 researchers, including 32 experienced TB researchers (19 current members of the CTR), 15 senior researchers new to the TB field, and 11 Early Stage Investigators (ESI). The overarching mission of the JHU TRAC is to advance TB research by promoting innovative, multidisciplinary collaborations and by recruiting, training and supporting junior Investigators, especially among UHRR groups, to develop the next generation of leaders in TB research. To this end, the JHU TRAC will focus on these four areas: 1) Enhance the integration, productivity and impact of JHU TB research; 2) Provide mentoring, support, and pilot funding for the next generation of TB researchers, and to increase the pipeline of junior investigators from UHRR groups; 3) Support TB researchers with direct services from a Clinical Core and three Scientific Cores; 4) Contribute to the END TB goals through global engagement, training, outreach, and collaboration with partners in high-burden countries. The JHU TRAC is organized into six Cores (Adminsitrative Core (AC); Developmental Core (DC); Clinical Core (CC); Microbiology, Immunology, Animal Modeling and Imaging (MIAMI) Core; Pharmacology and Pharmacometrics Core (PPC); and Bioinformatics, Modeling and Biostatistics Core (BMBC), which will interact closely with each other to promote synergy in TB research, and ensure that the utility and output of the JHU TRAC is greater than the sum of its parts.

摘要 — JHU TRAC 整体 结核病 (TB) 仍然是一个主要的全球健康问题，基础科学和临床科学的进步正在不断取得进展。 迫切需要在实现世界卫生组织《消灭结核病战略》减少结核病的目标方面取得进展 2015 年至 2035 年间，死亡人数减少 95%，新发病例增加 90%。约翰·霍普金斯大学 (JHU) 中心 结核病研究中心 (CTR) 在结核病发病机制、转化模型、诊断、药物方面一直处于全球领先地位 发展、药理学、公共卫生干预措施以及流行病学和经济模型 二十年。 CTR 和 JHU 的研究改变了结核感染的治疗方法， 疾病，阐明了结核病和艾滋病毒药物之间的相互作用，验证了新药物的功效和有效性 诊断工具，并为全球结核病控制循证政策的制定做出了贡献 结核病的流行病学和人口动态。然而，要在实现终结结核病的努力中取得进一步进展 目标，额外的创新、跨学科和有影响力的研究至关重要，新一代结核病 必须招募和培训科学家，特别是在全国卫生相关领域代表性不足的群体中 研究（UHRR）。我们组建了一支由来自多个部门的研究人员组成的多学科团队 四所约翰霍普金斯大学学院（医学、公共卫生、护理和工程），在微生物方面具有互补的专业知识 发病机制、免疫学、动物模型、影像学、临床试验、诊断、流行病学、药理学和 药理学、计算模型和生物统计学，为结核病研究提供附加值 约翰霍普金斯大学的企业优化了初级研究人员的培训机会，并为新的跨学科提供支持 合作，旨在解决结核病研究中的关键知识差距。 JHU TRAC 团队包括 58名研究人员，其中32名经验丰富的结核病研究人员（19名现任CTR成员），15名高级研究人员 结核病领域的新人，以及 11 名早期研究人员 (ESI)。 JHU TRAC 的首要使命是推动 通过促进创新、多学科合作以及招募、培训和支持来开展结核病研究 初级研究人员，特别是 UHRR 小组中的初级研究人员，以培养结核病研究的下一代领导者。到 为此，JHU TRAC 将重点关注以下四个领域： 1) 增强 JHU 的一体化、生产力和影响力 结核病研究； 2) 为下一代结核病研究人员提供指导、支持和试点资金，并 增加 UHRR 小组的初级调查员队伍； 3) 通过直接服务支持结核病研究人员 一个临床核心和三个科学核心； 4) 通过全球参与、培训、 与高负担国家的伙伴进行外展和合作。 JHU TRAC 分为六个核心 （行政核心（AC）；发展核心（DC）；临床核心（CC）；微生物学、免疫学、动物学 建模与成像（迈阿密）核心；药理学和药理学核心（PPC）；和生物信息学， 建模和生物统计核心（BMBC），它们将相互密切相互作用，以促进结核病的协同作用 研究，并确保 JHU TRAC 的效用和产出大于其各个部分的总和。